Pharmaceutical advances offer new options for health outcomes
Research presented at Digestive Disease Week (DDW) explores pharmaceutical advances for treating irritable bowel syndrome with diarrhea (IBS-D) and hepatitis C.
Diseases, Conditions, Syndromes
6 hours ago |
not rated yet |
0
Sofosbuvir shows promise for chronic hepatitis C infection
(HealthDay)—Sofosbuvir seems to be a promising treatment option for patients with chronic hepatitis C virus (HCV) infection, according to two studies published online April 23 in the New England Journal of ...
Diseases, Conditions, Syndromes
Apr 23, 2013 |
4 / 5 (1) |
0
|
Treatment for novel coronavirus shows promise in early lab tests
National Institutes of Health (NIH) scientists studying an emerging coronavirus have found that a combination of two licensed antiviral drugs, ribavirin and interferon-alpha 2b, can stop the virus from replicating ...
Diseases, Conditions, Syndromes
Apr 18, 2013 |
not rated yet |
0
Interferon-free therapies for hep C virus look promising
(HealthDay)—For untreated patients with hepatitis C virus (HCV), treatment with an oral nucleotide inhibitor of HCV polymerase, sofosbuvir, plus ribavirin seems effective for genotypes 1, 2, and 3; and ...
Diseases, Conditions, Syndromes
Jan 03, 2013 |
not rated yet |
0
Antiviral therapy may halve risk of liver cancer after chronic hepatitis C infection
Treating chronic hepatitis C infection with antiviral drugs could halve the risk of developing the most common form of liver cancer, in some cases, indicates an analysis of the published research in one of the new BMJ Op ...
Diseases, Conditions, Syndromes
Oct 22, 2012 |
5 / 5 (1) |
0
Abbott Labs rises on hepatitis C drug data (Update)
Abbott Laboratories said Monday that its experimental hepatitis C drug regimen cured 99 percent of patients in a midstage study with the most common and hardest-to-treat type of the disease.
Medications
Oct 15, 2012 |
not rated yet |
0
Prior alcohol consumption does not impair HCV treatment
(HealthDay)—For patients with hepatitis C virus (HCV) treated with pegylated interferon-alpha and ribavirin (P/R), drinking patterns and the amount of alcohol consumed before treatment do not impact treatment ...
Diseases, Conditions, Syndromes
Oct 11, 2012 |
not rated yet |
0
Will new drugs block hepatitis C virus in its tracks?
Targeted multi-drug treatments for hepatitis C patients that could stop the virus in its tracks have come a step closer, thanks to researchers at the University of Leeds, UK.
Diseases, Conditions, Syndromes
Jun 28, 2011 |
5 / 5 (1) |
0
